Top

Published in:

01-06-2011 | Review Article

HBV life cycle and novel drug targets

Authors: Daniel Grimm, Robert Thimme, Hubert E. Blum

Published in: Hepatology International | Issue 2/2011

Abstract

With up to 400 million affected people worldwide, chronic hepatitis B virus (HBV) infection is still a major health care problem. During the last decade, several novel therapeutic approaches have been developed and evaluated. In most regions of the world, interferon-α, and nucleos(t)ide analogues (NUCs) are currently approved. Despite major improvements, none of the existing therapies is optimal since viral clearance is rarely achieved. Recently, a better understanding of the HBV life cycle and the development of novel model systems of HBV infection have led to the development of novel antiviral strategies and drug targets. This review will focus on current and potential future drug targets in the HBV life cycle and strategies to modulate the virus–host interaction.

Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359(14):1486–500PubMedCrossRef

Thimme R, Blum HE. (Therapy of hepatitis B). Praxis (Bern 1994) 2006;95(36):1383–1388

ZF SeegerC, Mason WS. Hepadnaviruses. 5th ed. Philadelphia: Lippincott, Williams and Wilkins; 2007

Stein LL, Loomba R. Drug targets in hepatitis B virus infection. Infect Disord Drug Targets 2009;9(2):105–116PubMed

Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. J Hepatol 2010;52(2):282–284PubMedCrossRef

Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res 2008;134(1–2):235–249PubMedCrossRef

Balsano C, Alisi A. Viral hepatitis B: established and emerging therapies. Curr Med Chem 2008;15(9):930–939PubMedCrossRef

European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50(2):227–242CrossRef

Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351(15):1521–1531PubMedCrossRef

10.

Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009;51(3):581–592PubMedCrossRef

11.

Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008;89(Pt 1):1–47PubMedCrossRef

12.

Ank N, West H, Paludan SR. IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 2006;26(6):373–379PubMedCrossRef

13.

Stegmann KA, Bjorkstrom NK, Veber H, Ciesek S, Riese P, Wiegand J, Hadem J, Suneetha PV, Jaroszewicz J, Wang C, Schlaphoff V, Fytili P, Cornberg M, Manns MP, Geffers R, Pietschmann T, Guzman CA, Ljunggren HG, Wedemeyer H. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010;138(5):1885–1897PubMedCrossRef

14.

Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227–264PubMedCrossRef

15.

Dusheiko G, Antonakopoulos N. Current treatment of hepatitis B. Gut 2008;57(1):105–124PubMedCrossRef

16.

Robek MD, Boyd BS, Wieland SF, Chisari FV. Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci USA 2004;101(6):1743–1747PubMedCrossRef

17.

Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001;12(2):195–202PubMedCrossRef

18.

Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365(9454):123–129PubMedCrossRef

19.

Ank N, Paludan SR. Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors 2009;35(1):82–87PubMedCrossRef

20.

Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4(1):69–77PubMedCrossRef

21.

Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, Sorgeloos F, Ehl S, Mayer D, Kochs G, Schwemmle M, Gunther S, Drosten C, Michiels T, Staeheli P. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 2010;84(11):5670–5677PubMedCrossRef

22.

Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4(1):63–68PubMedCrossRef

23.

Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4(3):e1000017PubMedCrossRef

24.

Pagliaccetti NE, Chu EN, Bolen CR, Kleinstein SH, Robek MD. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology 2010;401(2):197–206PubMedCrossRef

25.

Doyle CM, Han J, Weigert MG, Prak ET. Consequences of receptor editing at the lambda locus: multireactivity and light chain secretion. Proc Natl Acad Sci USA 2006;103(30):11264–11269PubMedCrossRef

26.

Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res 2007;126(1–2):245–249PubMedCrossRef

27.

O’Brien TR. Interferon-alfa, interferon-lambda and hepatitis C. Nat Genet 2009;41(10):1048–1050PubMedCrossRef

28.

Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Carlos Lopez-Talavera J, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010 (Epub ahead of print)

29.

Kakumu S, Ishikawa T, Mizokami M, Orido E, Yoshioka K, Wakita T, Yamamoto M. Treatment with human gamma interferon of chronic hepatitis B: comparative study with alpha interferon. J Med Virol 1991;35(1):32–37PubMedCrossRef

30.

Weng HL, Wang BE, Jia JD, Wu WF, Xian JZ, Mertens PR, Cai WM, Dooley S. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol 2005;3(8):819–828PubMedCrossRef

31.

Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137(5):1593–1608, e1591–e1592

32.

Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, Brosgart CL, Woessner MA, Scott SA, Gray DF, Gardner SD. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008;48(5):728–735PubMedCrossRef

33.

Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352(26):2682–2695PubMedCrossRef

34.

Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351(12):1206–1217PubMedCrossRef

35.

Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009;51(4):787–791PubMedCrossRef

36.

Jang JH, Kim JW, Jeong SH, Myung HJ, Kim HS, Park YS, Lee SH, Hwang JH, Kim N, Lee DH. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat (Epub ahead of print)

37.

Kim BK, Oh J, Kwon SY, Choe WH, Ko SY, Rhee KH, Seo TH, Lim SD, Lee CH. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009;51(4):829–834PubMedCrossRef

38.

Yuen MF, Han KH, Um SH, Yoon SK, Kim HR, Kim J, Kim CR, Lai CL. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology 2010;51(3):767–776PubMedCrossRef

39.

Yuen MF, Kim J, Kim CR, Ngai V, Yuen JC, Min C, Kang HM, Shin BS, Yoo SD, Lai CL. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther 2006;11(8):977–983PubMed

40.

Yuen MF, Lee SH, Kang HM, Kim CR, Kim J, Ngai V, Lai CL. Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice. Antimicrob Agents Chemother 2009;53(5):1779–1785PubMedCrossRef

41.

Erion MD, van Poelje PD, Mackenna DA, Colby TJ, Montag AC, Fujitaki JM, Linemeyer DL, Bullough DA. Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther 2005;312(2):554–560PubMedCrossRef

42.

Herman BD, Votruba I, Holy A, Sluis-Cremer N, Balzarini J. The acyclic 2, 4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization. J Biol Chem 2010;285(16):12101–12108PubMedCrossRef

43.

Brunelle MN, Lucifora J, Neyts J, Villet S, Holy A, Trepo C, Zoulim F. In vitro activity of 2, 4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother 2007;51(6):2240–2243PubMedCrossRef

44.

Balzarini J, Pannecouque C, Naesens L, Andrei G, Snoeck R, De Clercq E, Hockova D, Holy A. 6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity. Nucleosides Nucleotides Nucleic Acids 2004;23(8–9):1321–1327PubMedCrossRef

45.

Babinet C, Farza H, Morello D, Hadchouel M, Pourcel C. Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. Science 1985;230(4730):1160–1163PubMedCrossRef

46.

Chisari FV, Pinkert CA, Milich DR, Filippi P, McLachlan A, Palmiter RD, Brinster RL. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science. 1985;230(4730):1157–1160PubMedCrossRef

47.

Sun D, Nassal M. Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus. J Hepatol 2006;45(5):636–645PubMedCrossRef

48.

Root MJ, Steger HK. HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 2004;10(15):1805–1825PubMedCrossRef

49.

Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005;79(3):1613–1622PubMedCrossRef

50.

Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von Weizsacker F, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26(3):335–341PubMedCrossRef

51.

Kock J, Blum HE. Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J Gen Virol 2008;89(Pt 5):1184–1191PubMedCrossRef

52.

Rosler C, Kock J, Kann M, Malim MH, Blum HE, Baumert TF, von Weizsacker F. APOBEC-mediated interference with hepadnavirus production. Hepatology 2005;42(2):301–309PubMedCrossRef

53.

Vartanian JP, Henry M, Marchio A, Suspene R, Aynaud MM, Guetard D, Cervantes-Gonzalez M, Battiston C, Mazzaferro V, Pineau P, Dejean A, Wain-Hobson S. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog 2010;6(5):e1000928PubMedCrossRef

54.

Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004;303(5665):1829PubMedCrossRef

55.

Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, Kubo M, Tsunoda T, Kamatani N, Kumada H, Puseenam A, Sura T, Daigo Y, Chayama K, Chantratita W, Nakamura Y, Matsuda K. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009;41(5):591–595PubMedCrossRef

56.

Lau GK, Ye D. Novel insights into the association between HLA-DP variants and persistent hepatitis B virus infection: a genome-wide association study. Gastroenterology 2010;138(1):394–396PubMedCrossRef

57.

Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006;130(3):823–837PubMedCrossRef

58.

Zimmerman KA, Fischer KP, Joyce MA, Tyrrell DL. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol 2008;82(16):8013–8021PubMedCrossRef

59.

Durantel D, Alotte C, Zoulim F. Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr Opin Investig Drugs 2007;8(2):125–129PubMed

60.

Mehta A, Carrouee S, Conyers B, Jordan R, Butters T, Dwek RA, Block TM. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology 2001;33(6):1488–1495PubMedCrossRef

61.

Stray SJ, Bourne CR, Punna S, Lewis WG, Finn MG, Zlotnick A. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci USA 2005;102(23):8138–8143PubMedCrossRef

62.

Bourne C, Lee S, Venkataiah B, Lee A, Korba B, Finn MG, Zlotnick A. Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle. J Virol 2008;82(20):10262–10270PubMedCrossRef

63.

Zhu X, Zhao G, Zhou X, Xu X, Xia G, Zheng Z, Wang L, Yang X, Li S. 2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly. Bioorg Med Chem Lett 2010;20(1):299–301PubMedCrossRef

64.

Wu GY, Zheng XJ, Yin CC, Jiang D, Zhu L, Liu Y, Wei L, Wang Y, Chen HS. Inhibition of hepatitis B virus replication by Bay 41–4109 and its association with nucleocapsid disassembly. J Chemother 2008;20(4):458–467PubMed

65.

Stray SJ, Zlotnick A. BAY 41–4109 has multiple effects on hepatitis B virus capsid assembly. J Mol Recognit 2006;19(6):542–548PubMedCrossRef

66.

Feld JJ, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res 2007;76(2):168–177PubMedCrossRef

67.

Delaney WE, Edwards R, Colledge D, Shaw T, Furman P, Painter G, Locarnini S. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother. 2002;46(9):3057–3060PubMedCrossRef

68.

Tseng YP, Kuo YH, Hu CP, Jeng KS, Janmanchi D, Lin CH, Chou CK, Yeh SF. The role of helioxanthin in inhibiting human hepatitis B viral replication and gene expression by interfering with the host transcriptional machinery of viral promoters. Antiviral Res 2008;77(3):206–214PubMedCrossRef

69.

Ying C, Li Y, Leung CH, Robek MD, Cheng YC. Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc Natl Acad Sci USA 2007;104(20):8526–8531PubMedCrossRef

70.

Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007;67(13):1947–1967PubMedCrossRef

71.

Keeffe EB, Rossignol JF. Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. World J Gastroenterol 2009;15(15):1805–1808PubMedCrossRef

72.

Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA, Puglisi JD, Rossignol JF, Glenn JS. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology 2009;137(5):1827–1835PubMedCrossRef

73.

Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008;77(1):56–63PubMedCrossRef

74.

Rossignol JF, Keeffe EB. Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. Future Microbiol 2008;3:539–545PubMedCrossRef

75.

Zundorf I, Dingermann T. siRNAs—your friend and helper? Pharm Unserer Zeit 2009;38(1):9–11PubMedCrossRef

76.

Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009;457(7228):426–433PubMedCrossRef

77.

Sun D, Rosler C, Kidd-Ljunggren K, Nassal M. Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites. J Hepatol 2010;52(6):817–826PubMedCrossRef

78.

Locarnini S. Therapies for hepatitis B: where to from here? Gastroenterology 2005;128(3):789–792PubMedCrossRef

79.

Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 1993;104(6):1818–1821PubMed

80.

Lau GK, Lok AS, Liang RH, Lai CL, Chiu EK, Lau YL, Lam SK. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 1997;25(6):1497–1501PubMedCrossRef

81.

Loggi E, Bihl F, Chisholm JV 3rd, Biselli M, Bontadini A, Vitale G, Ercolani G, Grazi GL, Pinna AD, Bernardi M, Brander C, Andreone P. Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. J Hepatol 2009;50(3):625–630PubMedCrossRef

82.

Bertoletti A, Gehring A. Therapeutic vaccination and novel strategies to treat chronic infection. Expert Rev Gastroenterol Hepatol 2009;3(5):561–569PubMedCrossRef

83.

Ciancio A, Rizzetto M. Thymalfasin in the treatment of hepatitis B and C. Ann NY Acad Sci 2010;1194:141–146PubMedCrossRef

84.

Zhang YY, Chen EQ, Yang J, Duan YR, Tang H. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J 2009;6:63PubMedCrossRef

85.

Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, Denis J, Brecho C. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001;34(6):917–921PubMedCrossRef

86.

Vandepapeliere P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican MI, Win KM, Trepo C, Cooksley G, Wettendorff M, Ferrari C. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007;25(51):8585–8597PubMedCrossRef

87.

Rahman F, Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000;31(2):521–527PubMedCrossRef

88.

Jung MC, Gruner N, Zachoval R, Schraut W, Gerlach T, Diepolder H, Schirren CA, Page M, Bailey J, Birtles E, Whitehead E, Trojan J, Zeuzem S, Pape GR. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: Induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 2002;20(29–30):3598–3612PubMedCrossRef

89.

Heathcote J, McHutchison J, Lee S, Tong M, Benner K, Minuk G, Wright T, Fikes J, Livingston B, Sette A, Chestnut R. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999;30(2):531–536PubMedCrossRef

90.

Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari FV, Furze J, Bartholomeuz R, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995;95(1):341–349PubMedCrossRef

91.

Akbar SM, Murakami H, Horiike N, Onji M. Dendritic cell-based therapies in the bench and the bedsides. Curr Drug Targets Inflamm Allergy 2004;3(3):305–310PubMedCrossRef

92.

Xu DZ, Zhao K, Guo LM, Li LJ, Xie Q, Ren H, Zhang JM, Xu M, Wang HF, Huang WX, Bai XF, Niu JQ, Liu P, Chen XY, Shen XL, Yuan ZH, Wang XY, Wen YM. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One 2008;3(7):e2565PubMedCrossRef

93.

Yao X, Zheng B, Zhou J, Xu DZ, Zhao K, Sun SH, Yuan ZH, Wen YM. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 2007;25(10):1771–1779PubMedCrossRef

Title: HBV life cycle and novel drug targets
Authors: Daniel Grimm
Robert Thimme
Hubert E. Blum
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: Hepatology International / Issue 2/2011
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-011-9261-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Vertical transmission of hepatitis C virus in low to middle socio-economic pregnant population of Karachi

Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers

Eplerenone reverses spironolactone-induced painful gynaecomastia in cirrhotics

Expression level of glutamine synthetase is increased in hepatocellular carcinoma and liver tissue with cirrhosis and chronic hepatitis B

Combined effect of pro- and anti-inflammatory cytokine gene polymorphisms on susceptibility to liver cirrhosis in Tunisian HCV-infected patients

Superior long-term outcomes after surgery in child-pugh class a patients with single small hepatocellular carcinoma compared to radiofrequency ablation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials